4/3
05:21 am
insm
Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]
Low
Report
Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]
4/1
02:31 pm
insm
Insmed (INSM) had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an "overweight" rating on the stock.
3/31
02:05 am
insm
Drugmakers delay some European launches with a wary eye on Trump's pricing policies 1 / 2 [Yahoo! Finance Canada]
Medium
Report
Drugmakers delay some European launches with a wary eye on Trump's pricing policies 1 / 2 [Yahoo! Finance Canada]
3/30
09:44 pm
insm
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% [Yahoo! Finance]
Medium
Report
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% [Yahoo! Finance]
3/30
08:43 am
insm
Insmed (INSM) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $212.00 price target on the stock.
Low
Report
Insmed (INSM) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $212.00 price target on the stock.
3/26
08:17 pm
insm
Columbia Select Large Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]
Low
Report
Columbia Select Large Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]
3/26
12:51 pm
insm
Insmed (INSM) had its price target raised by HC Wainwright from $230.00 to $245.00. They now have a "buy" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by HC Wainwright from $230.00 to $245.00. They now have a "buy" rating on the stock.
3/25
10:56 am
insm
Insmed (INSM) had its price target raised by Mizuho from $204.00 to $206.00. They now have an "outperform" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Mizuho from $204.00 to $206.00. They now have an "outperform" rating on the stock.
3/24
05:15 pm
insm
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well [Seeking Alpha]
Medium
Report
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well [Seeking Alpha]
3/24
11:48 am
insm
Insmed (INSM) had its price target raised by Leerink Partners from $210.00 to $215.00. They now have an "outperform" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Leerink Partners from $210.00 to $215.00. They now have an "outperform" rating on the stock.
3/24
09:50 am
insm
Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.
3/24
08:42 am
insm
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
Medium
Report
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
3/24
08:30 am
insm
Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.
Medium
Report
Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.
3/23
09:35 pm
insm
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]
Medium
Report
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]
3/23
05:59 pm
insm
Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]
Medium
Report
Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]
3/23
12:45 pm
insm
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
3/23
12:32 pm
insm
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
Low
Report
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
3/23
10:27 am
insm
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
Low
Report
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
3/23
09:49 am
insm
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
3/23
07:33 am
insm
S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]
Low
Report
S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]
3/23
07:09 am
insm
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]
Low
Report
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]
3/23
07:00 am
insm
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
Low
Report
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
3/16
10:58 am
insm
Insmed (INSM) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Insmed (INSM) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/10
11:02 am
insm
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/5
07:00 am
insm
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)